| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| Cost of Revenue | $0 | — | — |
| Gross Profit | $0 | — | -100.0% |
| R&D Expense | $153.4M | — | — |
| SG&A Expense | $183K | — | +60.3% |
| Operating Income | -$153.6M | — | — |
| Interest Expense | $50K | — | — |
| Pre-tax Income | -$153.7M | — | — |
| Income Tax | $0 | — | — |
| Net Income | -$153.7M | — | — |
| EPS (Diluted) | -$2.08 | — | — |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Accounts Receivable | $3K | +0.0% | — |
| Current Assets | $55K | -41.9% | +542.3% |
| Total Assets | $114K | -85.9% | +10.2% |
| Current Liabilities | $3.5M | +2124.3% | +1115.0% |
| Total Liabilities | $4.1M | +2199.5% | +1102.5% |
| Stockholders' Equity | -$4.0M | -741.2% |
| Line Item | 2025-10-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$218K | — | -4674.5% |
| Financing Cash Flow | $180K | — | +4412.0% |
| -1573.1% |